Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Arcadia Biosciences (RKDA) Net Income towards Common Stockholders (2016 - 2024)

Arcadia Biosciences (RKDA) has disclosed Net Income towards Common Stockholders for 12 consecutive years, with -$1.2 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Net Income towards Common Stockholders fell 168.37% year-over-year to -$1.2 million, compared with a TTM value of -$1.7 million through Sep 2025, down 178.22%, and an annual FY2024 reading of -$2.7 million, down 231.43% over the prior year.
  • Net Income towards Common Stockholders was -$1.2 million for Q3 2025 at Arcadia Biosciences, down from -$501000.0 in the prior quarter.
  • Across five years, Net Income towards Common Stockholders topped out at $4.8 million in Q4 2023 and bottomed at -$16.1 million in Q4 2021.
  • Average Net Income towards Common Stockholders over 5 years is -$2.4 million, with a median of -$1.1 million recorded in 2022.
  • The sharpest move saw Net Income towards Common Stockholders soared 568.02% in 2023, then crashed 715.47% in 2024.
  • Year by year, Net Income towards Common Stockholders stood at -$16.1 million in 2021, then surged by 93.56% to -$1.0 million in 2022, then skyrocketed by 568.02% to $4.8 million in 2023, then crashed by 100.54% to -$26000.0 in 2024, then tumbled by 4338.46% to -$1.2 million in 2025.
  • Business Quant data shows Net Income towards Common Stockholders for RKDA at -$1.2 million in Q3 2025, -$501000.0 in Q2 2025, and -$26000.0 in Q4 2024.